CoImmune Announces Publication of Preclinical Results with SEAKER Cells in Solid Tumor Melanomas

2023-07-26

免疫疗法细胞疗法

- SEAKER cells localize specifically to tumors and convert bioactive prodrugs into therapeutic anticancer drugs in mouse models - DURHAM, N.C., July 26, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the publication of preclinical results with Synthetic Enzyme-Armed Killer (SEAKER) cells in solid tumor melanomas in the peer-reviewed journal Cancer Immunology Research. The recently published paper titled, "Host Interactions with Engineered T cell Micropharmacies," describes seminal work by researchers at Memorial Sloan Kettering Cancer Center (MSK) including David A. Scheinberg, M.D., Ph.D., Chairman of the Center for Experimental Therapeutics and Deputy Director, Therapeutic Discovery, Sloan Kettering Institute (SKI), and Derek S. Tan, Ph.D., Chairman of the Chemical Biology Program, SKI. The work evaluates SEAKER cells designed to target solid-tumor melanomas in syngeneic mouse models using specific targeting with T cell receptor (TCR) engineered T cells. Results demonstrate that SEAKER cells localize specifically to tumors and activate bioactive prodrugs, providing efficacy against melanoma tumors in immunocompetent hosts. "As we continue to advance a development program based on our proprietary chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform, we are investigating technologies that could help deliver additional agents locally to tumor sites to mitigate tumor escape by loss of targeted antigens and tumor induced immunosuppression," said Charles Nicolette, Ph.D., Chief Executive Officer of CoImmune. "Our goal is to overcome the barriers to the treatment of solid tumors, and this new publication evaluating SEAKER cells in solid tumor melanoma models is another encouraging step in that direction." CoImmune has acquired the rights to several technologies developed at MSK including SEAKER cells that combine the target-seeking power of immune cells with the ability to locally generate a potent anticancer drug at the tumor site without systemic toxicity, also referred to as a "micropharmacy." "Genetically engineered, cytotoxic, adoptive T cells localize to antigen positive cancer cells inside patients, but tumor heterogeneity and multiple immune escape mechanisms have prevented the eradication of most solid tumors," said Dr. Scheinberg. "SEAKER cells can be designed to express a prodrug converting enzyme to achieve high active anti-tumor drug levels at tumor sites. This preclinical work demonstrates that the SEAKER platform is applicable to many adoptive cell therapies." About CoImmune, Inc. CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them. For more information visit . MSK Disclosure: Dr. Scheinberg and Dr. Tan have financial interests related to CoImmune. MSK has institutional financial interests related to CoImmune. Investor Contact: Lori Harrelson Chief Financial Officer CoImmune, Inc. lharrelson@coimmune.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构